Non-prescribed use of gabapentinoids
Clinics in Integrated Care, ISSN: 2666-8696, Vol: 21, Page: 100164
2023
- 1Citations
- 1Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations1
- Citation Indexes1
- CrossRef1
- Captures1
- Readers1
Review Description
The gabapentinoid drugs gabapentin and pregabalin are medications used clinically across a range of neurological and psychiatric conditions. They have analgesic, anticonvulsant and anxiolytic effects. Their specific licensed indications differ, and vary across countries, but include certain neurological problems such as focal seizures, peripheral neuropathic pain, spasticity in multiple sclerosis, and muscular symptoms in motor neurone disease, and the psychological condition of generalized anxiety disorder. However, in many countries, gabapentin and pregabalin are frequently prescribed outside the terms of their market authorisations, and non-prescribed use has become widespread and troublesome in many populations. Increasing concerns regarding non-prescribed use have led some regulatory authorities to designate gabapentin and pregabalin as controlled substances, with accompanying regulations regarding prescriptions. This review describes the pharmacological properties of gabapentin and pregabalin, highlights evidence regarding efficacy and tolerability, summarises the findings of investigations of potential hazards with these drugs, and concludes with guidance on the clinical management of non-prescribed use.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know